Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
23,944.40
(
-0.29%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
100.89
(
2.63%
)
Bitcoin
73,712.46
(
-1.51%
)
News Focus
News Focus
Post# of 257250
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: MotionMan post# 88876

Monday, 01/11/2010 9:11:34 PM

Monday, January 11, 2010 9:11:34 PM

Post# of 257250
MNTA:

listening to Teva's Jan 7th webcast. Bill Marth was adamant about believing that generic Copaxone applicants will have to run comprehensive clinical studies. He does not believe anyone can fully characterize a polypeptide with permutations up to 10 to the 28th power.

The 10^28 figure is irrelevant. MNTA replicates branded Copaxone by reverse engineering the process that generates the permutations, not by replicating each of the permutations directly. Please see #msg-30647865, which is an entry in the MNTA ReadMeFirst.

Bill Marth knows all this, of course.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now